Celeste Bello, MD
Hematology & Oncology · Tampa, FLNPI 1942364856
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,020 of the $8,082 with a category attached, or 86.9%. 5 manufacturers reported payments, led by Seagen Inc. at 59.1% of the total. Reporting peaked in 2020 at $5,920 and has fallen 96.1% since, to $228 in 2023.
Across 13 payments — averaging $621.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$5K
- Gilead$3K
- Bristol Myers Squibb$565
- Acrotech Biopharma Inc.$26
- Amgen$15
Across 10 payments — averaging $7847.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$40K
- E.r. Squibb & Sons, L.L.C.$37K
- Bristol Myers Squibb$2K
What the payments were for
- Consulting fees$7,02087%
- Speaking & faculty fees$5657%
- Food & beverage$3765%
- Education$1211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 8 | $4,776 |
| Gilead | 1 | $2,700 |
| Bristol Myers Squibb | 1 | $565 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,082 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 39 | $592,511 |
| ImbruvicaIbrutinib | 32 | $554,882 |
| CalquenceAcalabrutinib Maleate | 19 | $291,516 |
| Gabapentin | 14 | $155 |
| Oxycodone Hcl | 15 | $155 |
| Prednisone | 21 | $34 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.